Model Comparisons of the Cost Effectiveness of Rubella Vaccination Method in Japanese Adults

• Published in: Vaccines (Basel) Vol. 9; no. 3; p. 233
• Main Authors: Itatani, Tomoya, Horiike, Ryo, Nakai, Hisao, Taira, Kazuya, Honda, Chika, Shirai, Fumie, Konishi, Kaoru
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 08.03.2021; MDPI AG
• Subjects: congenital rubella syndrome; cost effectiveness; rubella; vaccine; vaccine; rubella; congenital rubella syndrome; cost effectiveness
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines9030233

The number of rubella cases has increased in Japan, especially among adults. Rubella infection in pregnant females can lead to congenital rubella syndrome (CRS). The Japanese government is promoting vaccination to prevent CRS. This study performs a cost-effectiveness analysis of the following four methods: (1) females who wished to become pregnant and partners, with an antibody-titer test; (2) females only, with an antibody-titer test; (3) females and males, without an antibody-titer test; (4) females only, without an antibody-titer test. A decision tree model with a hypothetical cohort of 500 males and 500 females was used for the analysis, and the parameters were obtained from previous studies. The number of avoidances of CRS was defined as the effect. Compared to the case where methods were not implemented, the number of CRS cases that can be prevented by implementing the methods was 0.0115589 by (1) and (3) and 0.0147891 by (2) and (4). The cost effectiveness of (1) to (4) was 287,413,677 JPY, 135,050,529 JPY, 388,524,974 JPY, and 197,744,219 JPY, respectively (1 JPY = 0.00963247 USD). Method (2) was the most cost-effective and did not change by sensitivity analysis. We conclude that the vaccination for females only with an antibody-titer test is recommended.